Acadia Pharmaceuticals Stock Trading Halted Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs on Acadia Pharmaceuticals (ACAD): 'We expect the stock to move lower on Tuesday given the results of the vote'
June 21, 2022 10:18 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Neutral rating and $20.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)
The analyst comments "The FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted against pimavanserin (Nuplazid) as an effective treatment for hallucinations and delusions in Alzheimer's disease psychosis (ADP) (Vote: 9 No/3 Yes), and recommended... More
Acadia Pharma (ACAD) Resume Trading, Down 32%
June 21, 2022 7:11 AM EDTAcadia Pharma (NASDAQ: ACAD) Resume Trading, Down 32%
... More